Direkt zum Inhalt
Merck

P0100

Sigma-Aldrich

Psilocybin

≥98% (HPLC), solid

Synonym(e):

3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl phosphate

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C12H17N2O4P
CAS-Nummer:
Molekulargewicht:
284.25
EG-Nummer:
MDL-Nummer:
UNSPSC-Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

Form

solid

Arzneimittelkontrolle

USDEA Schedule I; regulated under CDSA - not available from Sigma-Aldrich Canada

Löslichkeit

H2O: >20 mg/mL

Lagertemp.

−20°C

SMILES String

CN(C)CCc1c[nH]c2cccc(OP(O)(O)=O)c12

Biochem./physiol. Wirkung

Psilocybin is a hallucinogenic serotonin 1A and 2A agonist and psychotomimetic. It is the minor hallucinogenic component of Teonanácatl, the sacred mushroom of Mexico. Psilocybin produces muscle relaxation, dilation of pupils, vivid visual and auditory distortions, and emotional disturbances.

Piktogramme

Health hazardExclamation mark

Signalwort

Danger

Gefahreneinstufungen

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 1

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Gloves, type N95 (US)


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Jonathan P Roiser et al.
Current biology : CB, 22(7), R231-R233 (2012-04-14)
Two recent studies report changes in human brain responses after exposure to psilocybin, the active ingredient of hallucinogenic mushrooms. Psilocybin increased sensory cortex responses during emotional recollection, but decreased resting-state blood flow in prefrontal cortex, with potential implications for treating depression.
Opening doors of perception: psychedelic drugs and end-of-life care.
Norra Macready
Journal of the National Cancer Institute, 104(21), 1619-1620 (2012-10-30)
Erich Studerus et al.
PloS one, 7(2), e30800-e30800 (2012-03-01)
Responses to hallucinogenic drugs, such as psilocybin, are believed to be critically dependent on the user's personality, current mood state, drug pre-experiences, expectancies, and social and environmental variables. However, little is known about the order of importance of these variables
Hallucinogen actions on human brain revealed.
Hyeong-Min Lee et al.
Proceedings of the National Academy of Sciences of the United States of America, 109(6), 1820-1821 (2012-02-07)
Matthew W Johnson et al.
Drug and alcohol dependence, 123(1-3), 132-140 (2011-12-02)
Psilocybin is a well-characterized classic hallucinogen (psychedelic) with a long history of religious use by indigenous cultures, and nonmedical use in modern societies. Although psilocybin is structurally related to migraine medications, and case studies suggest that psilocybin may be efficacious

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.